Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-07-20
2011-12-20
Ward, Paul V. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S242000
Reexamination Certificate
active
08080549
ABSTRACT:
This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
REFERENCES:
patent: 5292740 (1994-03-01), Burri et al.
patent: 5696116 (1997-12-01), Clozel et al.
patent: 5846514 (1998-12-01), Foster et al.
patent: 5945448 (1999-08-01), Ninomiya et al.
patent: 6087368 (2000-07-01), Macor et al.
patent: 6139971 (2000-10-01), Bruchlaus et al.
patent: 6221335 (2001-04-01), Foster
patent: 6440710 (2002-08-01), Keinan et al.
patent: 6586391 (2003-07-01), Banting et al.
patent: 6603008 (2003-08-01), Ando et al.
patent: 6635648 (2003-10-01), Adams et al.
patent: 6696719 (2004-02-01), Yamamoto
patent: 6869970 (2005-03-01), Marti
patent: 7019013 (2006-03-01), Eggenweiler et al.
patent: 7208602 (2007-04-01), Pissarnitski et al.
patent: 7517990 (2009-04-01), Ito et al.
patent: 2003/0144300 (2003-07-01), Magee et al.
patent: 2004/0063719 (2004-04-01), Adams et al.
patent: 2004/0063731 (2004-04-01), Eggenweiler et al.
patent: 2006/0205733 (2006-09-01), Dixon et al.
patent: 2007/0037831 (2007-02-01), Cuffie-Jackson et al.
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0197695 (2007-08-01), Potyen et al.
patent: 2008/0103122 (2008-05-01), Veltri
patent: 2009/0005394 (2009-01-01), Harbeson
patent: 2009/0069351 (2009-03-01), Czarnik
patent: WO 95/26325 (1995-10-01), None
patent: WO 96/38173 (1996-05-01), None
patent: WO 01/05120 (2001-01-01), None
patent: WO 02/074034 (2002-09-01), None
patent: WO 2004/017993 (2004-03-01), None
patent: WO 2004/082637 (2004-09-01), None
patent: WO 2005/101608 (2005-10-01), None
patent: WO 2007/016361 (2007-02-01), None
patent: WO 2007/118651 (2007-10-01), None
patent: WO 2008/088727 (2008-07-01), None
Hopfgartner, G., “Fragmentation of Bosentan® (Ro 47/0203) in Ionspray Mass Spectrometry After Collision-induced Dissociation at Low Energy: a Case of Radical Fragmentation of an Even-electron Ion,”Journal of Mass Spectrometry, 31:69-76 (1996).
Lausecker, B. and Hopfgartner, G., “Determination of an Endothelin Receptor Antagonist in Human Plasma by Narrow-bore Liquid Chromatography and Ionspray Tandem Mass Spectrometry,”Journal of Chromatography, 712(1):75-83 (1995).
Lausecker, B., and Fischer, G., “Development of a Liquid Chromatographic/Tandem Mass Spectrometric Assay for a new Endothelin Receptor Antagonist, and its Application to Dog Plasma Samples Generated After Simultaneous I.V. and P.O. Administration of the Unlabeled and Deuterium-Labeled Forms of this Antagonist,”Journal of Mass Spectrometry, 38(6):649-658 (2003).
Gideon, Paul A., et al., “Bosentan Decreases the Plasma Concentration of Sildenafil when Coprescribed in Pulmonary Hypertension,”British Journal of Clinical Pharmacology, 60(1):107-112, (2005).
Fisher, M.B. et al., “The Complexities Inherent in Attempts to Decrease Drug Clearance by Blocking Sites of CYP-Mediated Metabolism,”Curr. Opin. Drug Discov., 9(1): 101-109 (Jan. 2006).
Kushner, D.J. et al., “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,”Can. J. Physiol. Pharmacol., 77(2): 79-88 (Feb. 1999).
Prescribing Information for TRACLEER® (bosentan), NDA 21-290/S-006 and S-007, pp. 3-22 (month not available).
Harrington, P.J., et al., Org. Process R&D 2002, 6(2), 120.
International Search Report dated Sep. 17, 2008, issued in PCT/US2008/000384.
Written Opinion of the International Searching Authority dated Sep. 17, 2008, issued in PCT/US2008/000384.
Notification Concerning Transmittal of International Preliminary Report on Patentability, International Application No. PCT/US2008/000384, Date of Mailing Jul. 23, 2009.
Baillie, T. A., “The Use of Stable Isotopes in Pharmacological Research,”Pharmacological Reviews, 33(2): 81-132 (1981).
Browne, T. R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,”J. Clin. Pharmacol., 38: 213-220 (1998).
Cherrah, Y., et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,”Biomedical and Environmental Mass Spectrometry, 14: 653-657 (1987).
Dyck, L. E., et al., “Effects of Deuterium Substitution on the Catabolism of β-Phenylethylamine: An in Vivo Study,”Journal of Neurochemistry, 46(2): 399-404 (1986).
Foster, A. B., “Deuterium Isotope Effects in Studies of Drug Metabolism,”Trends in Pharmacological Sciences, 5: 524-527 (1984).
Foster, A. B., “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,”Advances in Drug Research, 14: 1-40 (1985).
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,”Biomedical and Environmental Mass Spectrometry, 15: 243-247 (1988).
Haskins, N. J., “The Application of Stable Isotopes in Biomedical Research,”Biomedical Mass Spectrometry, 9(7): 269-277 (1982).
Honma S., et al., “The Metabolism of Roxatidine Acetate Hydrochloride,”Drug Metabolism and Disposition, 15(4): 551-559 (1987).
Pieniaszek, H. J., et al., “Moricizine Bioavailability via Simultaneous, Dual, Stable Isotope Administration: Bioequivalence Implications,”J. Clin. Pharmacol, 39: 817-825 (1999).
Tonn G. R., et al., “Simultaneous Analysis of Diphenhydramine and a Stable Isotope Analog (2H10) Diphenhydramine Using Capillary Gas Chromatography with Mass Selective Detection in Biological Fluids from Chronically Instrumented Pregnant Ewes,”Biological Mass Spectrometry, 22: 633-642 (1993).
Ubeaud, G., “Bosentan, a New Endothelin Receptor Antagonist: Prediction of the Systemic Plasma Clearance in Man From Combined in vivo and in vitro Data,”Xenobiotica, 25(12): 1381-1390 (1995).
Wolen, R. L., “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,”J. Clin. Pharmacol., 26: 419-424 (1986).
Park, B.K., et al., “Metabolism of Fluorine-Containing Drugs,”Annu. Rev. Pharmacol. Toxicol., 41:443-470 (2001).
Office Action, U.S. Appl. No. 12/008,698, Date of Mailing: Sep. 24, 2010.
Office Action, U.S. Appl. No. 12/008,698, Date of Mailing: Jun. 2, 2011.
CoNCERT Pharmaceuticals, Inc.
Hamilton Brook Smith & Reynolds P.C.
Ward Paul V.
LandOfFree
Endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endothelin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4259364